Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod-Reference-Cited by-同舟云学术

Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod

Published:2022-04 Issue: Volume:60 Page:103724
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Capuano Rocco,Bisecco Alvino,Conte Miriana,Donnarumma Giovanna,Altieri Manuela,Grimaldi Elena,Franci Gianluigi,Chianese Annalisa,Galdiero Massimiliano,Coppola Nicola,Tedeschi Gioacchino,Gallo Antonio

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference19 articles.

1. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies;Achiron;Ther. Adv. Neurol. Disord.,2021

2. Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: up to 6 months cross-sectional study;Achiron;J. Neuroimmunol.,2021

3. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy;Apostolidis;Nat. Med.,2021

4. Baden L.R., Sahly HM El, Essink B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. https://doi.org/101056/NEJMoa2035389 2020; 384: 403–416.

5. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study;Bar-Or;Neurology,2020

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients;Journal of Neurology;2023-11-20

2. SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose;Journal of Neurology;2023-11-03

3. Long-Term Immune Response Profiles to SARS-CoV-2 Vaccination and Infection in People with Multiple Sclerosis on Anti-CD20 Therapy;Vaccines;2023-09-07

4. Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton’s tyrosine kinase inhibitor;Multiple Sclerosis Journal;2023-08-25

5. Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies;Journal of Neurology;2023-08-17